Tag Archives: Biogen Inc.

Biogen’s poster presentation for Alzheimer’s candidate hardly noticed at London AAIC meeting as market focuses on quarterly results instead; start accumulating.

Biogen Inc. (Cambridge MA) laid out long-term plans to strengthen its core multiple sclerosis (MS) business, develop more neuroscience drugs and shop for late-stage assets, after reporting robust second-quarter results,… Read more »

Update: CDC data say docs still making billions from Pharma, med device companies; my personal take.

The News: It’s been a few years since the US government unveiled its Open Payments (OP) database, a collection of drug and device makers’ payments to healthcare providers. The data-collection… Read more »

CAR-T Therapy: Personalized medicine with the promise of a cure; payers will decide who gets it

The News: Swiss drug giant Novartis AG has drawn widespread praise and a rising dose of controversy pertaining to its breakthrough CAR-T therapy CTL019. The medicine is under review to… Read more »

Biogen spinoff Bioverativ buys Bristol-Myers’ iPierian spinout True North for $825 million; deal shows how to get several bites at the same assets

The News: Bioverativ Inc. (Waltham MA) announced that it entered into a definitive agreement to acquire True North Therapeutics Inc. (South San Francisco) for up to $825 million, including an… Read more »

Healthcare stocks primed for comeback in 2017? Here are Steve’s top picks

The population of the world, and the US and developed nations in particular, is growing and getting older, while the costs of keeping people healthy and living longer are exploding…. Read more »

New Biogen pick for CEO inherits tough job; markets aren’t exactly enthralled–yet

Biogen Inc. (Cambridge MA) said Monday (December 19, 2016) it has named veteran biopharmaceutical executive Michel Vounatsos, head of the company’s commercial organization, its next chief executive. Mr. Vounatsos will succeed George Scangos, who announced earlier this… Read more »

Lilly Alzheimer’s drug, like so many others, fails; will true breakthrough happen this century?

Eli Lilly & Co. (Indianapolis RIN) said its experimental Alzheimer’s treatment failed to slow loss of cognitive ability in patients with mild symptoms, a major setback for the company and millions of… Read more »

Study Suggests Revolutionary Drug Could Benefit Patients with Early Stage Alzheimer’s

A trial of a new Alzheimer’s drug has shown it could benefit patients in the earliest stages of the disease, raising hopes that a treatment for the devastating condition may… Read more »

Biogen’s 2Q Profit Crushes Views; CEO to Depart

Biogen Inc. (Cambridge MA) stock jumped Thursday after the drugmaker reported strong sales of some of its newest treatments for multiple sclerosis and hemophilia. The company’s net income and sales… Read more »